4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 25c

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($0.98), $0.25 worse than the analyst estimate of ($0.73).

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• Old Dominion Freight Line (ODFL) Reiterated at Buy by Stifel Amid Seasonally Softer Q4/Q1
• Microsoft (MSFT) PT Raised to $530 at Stifel on Accelerating M365 Copilot Momentum
• Guggenheim Reiterates Neutral Rating on Lululemon (LULU)